SEP
AMRX icon

Signature Equity Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

Signature Equity Partners’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.4K Sell
4,068
-150
-4% -$2.06K 0.03% 353
2026
Q1 		$52.4K Sell
4,218
-87
-2% -$1.17K 0.03% 399
2025
Q4 		$54.2K Buy
+4,305
New +$49.3K 0.03% 378

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Signature Equity Partners's AMRX Position: Q2 2026 in Review

Signature Equity Partners reduced its Amneal Pharmaceuticals (AMRX) stake by 3.6% in Q2 2026, selling an estimated $2.06K and leaving 4,068 shares worth $70.4K. The position accounts for 0.03% of the portfolio, ranked #353.

Signature Equity Partners first reported a position in AMRX in Q4 2025 and has held it in 3 quarters since. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Signature Equity Partners held 4,068 shares of Amneal Pharmaceuticals worth $70.4K as of Q2 2026.
  • Signature Equity Partners sold 150 Amneal Pharmaceuticals shares in Q2 2026, an estimated $2.06K.
  • Amneal Pharmaceuticals made up 0.03% of Signature Equity Partners's portfolio in Q2 2026, its #353 holding.
  • Signature Equity Partners first reported a position in Amneal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.